Robert Yu, CEO of Yuyu Pharma, is attending two large-scale biopharmaceutical conferences held in Germany, BIO-Europe and CPHI, for the advancement of Yuyu’s entry into the European market.  

While attending BIO-Europe (Leipzig) and CPHI (Frankfurt), Robert Yu will focus on meeting with contract research organizations, doctors, and pharmacy faculty members in preparation for clinical trials in Europe for Yuyu’s new drug pipeline product, YP-P10. Yuyu Pharma is currently conducting Phase 2 clinical trials for YP-P10 in the United States.

Additionally, Robert Yu plans to meet with global pharmaceutical companies to discuss potential collaboration opportunities as well as meet with European officials in connection with regulatory affairs and drug registration. Furthermore, there are plans to discuss the development of modified drugs in soft gel capsule formulation, a formulation in which Yuyu has considerable expertise.
  

Robert Yu said “Starting with attending these conferences, Yuyu Pharma will continue to endeavor to advance Yuyu into the European market. We have received positive feedback about Yuyu’s new drug pipeline from members of the Europe’s biopharmaceutical industry.”